Eculizumab therapy in paroxysmal nocturnal hemoglobinuria results in a rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH - Weitz,I.C.; Ghods,M.; Rochanda,L.; Razavi,P.; Liebman,H. (Blood, 2008)